 VICTORIA, British Columbia--BUSINESS WIRE--- IPA Deltavariant--IMMUNOPRECISE ANTIBODIES LTD. the Company or IPA NASDAQ: IPA TSX VENTURE: IPA a leader in full-service, therapeutic antibody discovery and development, today announced financial results for the full fiscal year 2021 ended April 30, 2021. Fiscal 2021 Financial Summary Earned revenues of 17.9 million, a 27 increase which includes a sale through Talem of an internally generated therapeutic antibody for 1.2 million, core CRO business up 19 